A conference was recently held in Liverpool (UK) to address ‘very large disparities in recommendations and services for TB prevention and drug-resistant TB care between limited and well-resourced settings’. I would be interested to hear more from HIFA members about ‘disparities in recommendations’. Presumably WHO international recommendations are universal and not contributing to these disparities? One would expect the disparities to arise not from these recommendations but from differences in the way that MoHs develop national policy (taking into account the burden of disease, available funding and so on)?
‘On October 27, 2016, in Liverpool, UK, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health.
‘The symposium, “Stop Double Standards: From Prevention through Cure to ZERO TB,” focused on biomedical TB prevention and in treating drug-resistant TB. We know both of these areas are essential to an effective TB response, yet very large disparities in recommendations and services for TB prevention and drug-resistant TB care persist between limited and well-resourced settings. Opening and closing speakers provided overviews on the scientific, human rights, and patient perspectives on the importance of ending double standards in TB prevention and drug-resistant TB care. Two panels composed of legal, activist, implementer, and researcher experts further discussed and provided ideas for a way forward. Question and answer sessions followed each panel.’
Video recordings of the event are available here:
Let’s build a future where people are no longer dying for lack of healthcare knowledge – Join HIFA: www.hifa.org